RU2002102701A - Stable oral hydrogel-forming, pharmaceutical composition, method for its preparation, method for preventing changes in drug release, method for increasing physical stability of the oral composition - Google Patents

Stable oral hydrogel-forming, pharmaceutical composition, method for its preparation, method for preventing changes in drug release, method for increasing physical stability of the oral composition

Info

Publication number
RU2002102701A
RU2002102701A RU2002102701/15A RU2002102701A RU2002102701A RU 2002102701 A RU2002102701 A RU 2002102701A RU 2002102701/15 A RU2002102701/15 A RU 2002102701/15A RU 2002102701 A RU2002102701 A RU 2002102701A RU 2002102701 A RU2002102701 A RU 2002102701A
Authority
RU
Russia
Prior art keywords
iron oxide
drug
oxide pigment
pharmaceutical composition
stable oral
Prior art date
Application number
RU2002102701/15A
Other languages
Russian (ru)
Other versions
RU2220715C2 (en
Inventor
Казухиро САКО
Тоёхиро САВАДА
Кеиити ЁСИХАРА
Тацунобу ЁСИОКА
Сунсуке ВАТАНАБЕ
Original Assignee
Яманоути Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Яманоути Фармасьютикал Ко., Лтд. filed Critical Яманоути Фармасьютикал Ко., Лтд.
Publication of RU2002102701A publication Critical patent/RU2002102701A/en
Application granted granted Critical
Publication of RU2220715C2 publication Critical patent/RU2220715C2/en

Links

Claims (9)

1. Стабильная пероральная фармацевтическая композиция, включающая лекарственное средство, гидрофильное основание и полиэтиленоксид, и которая представляет собой препарат с пролонгированным высвобождением матричного типа, отличающаяся тем, что включает желтый железооксидный пигмент и/или красный железооксидный пигмент в количестве, эффективном для стабилизации препарата с пролонгированным высвобождением матричного типа.1. A stable oral pharmaceutical composition comprising a drug, a hydrophilic base and polyethylene oxide, and which is a matrix-type sustained release preparation, characterized in that it includes yellow iron oxide pigment and / or red iron oxide pigment in an amount effective to stabilize the drug with prolonged matrix type release. 2. Стабильная пероральная фармацевтическая композиция по п.1, отличающаяся тем, что количество добавляемого желтого железооксидного пигмента и/или красного железооксидного пигмента составляет не менее чем 0,3% от массы таблетки.2. A stable oral pharmaceutical composition according to claim 1, characterized in that the amount of added yellow iron oxide pigment and / or red iron oxide pigment is not less than 0.3% by weight of the tablet. 3. Стабильная пероральная фармацевтическая композиция по п.1 или 2, отличающаяся тем, что количество добавляемого желтого железооксидного пигмента составляет от 1 до 20 мас.% от массы препарата.3. A stable oral pharmaceutical composition according to claim 1 or 2, characterized in that the amount of added yellow iron oxide pigment is from 1 to 20 wt.% By weight of the drug. 4. Стабильная пероральная фармацевтическая композиция по п.1 или 2, отличающаяся тем, что количество добавляемого красного железооксидного пигмента составляет от 5 до 20 мас.% от массы препарата.4. A stable oral pharmaceutical composition according to claim 1 or 2, characterized in that the amount of added red iron oxide pigment is from 5 to 20 wt.% By weight of the drug. 5. Способ получения стабильной пероральной фармацевтической композиции, включающий добавление желтого железооксидного пигмента и/или красного железооксидного пигмента в количестве, эффективном для стабилизации препарата с пролонгированным высвобождением матричного типа, включающего лекарственное вещество, гидрофильное основание и полиэтиленоксид.5. A method of obtaining a stable oral pharmaceutical composition, comprising adding yellow iron oxide pigment and / or red iron oxide pigment in an amount effective to stabilize the drug with a sustained release matrix type comprising a drug substance, a hydrophilic base and polyethylene oxide. 6. Способ получения стабильной пероральной фармацевтической композиции по п.5, отличающийся тем, что в указанный препарат добавляют желтый железооксидный пигмент с использованием, по меньшей мере, одного способа, выбранного из группы, состоящей из нанесения покрытия, гранулирования и перемешивания.6. A method of obtaining a stable oral pharmaceutical composition according to claim 5, characterized in that yellow iron oxide pigment is added to said preparation using at least one method selected from the group consisting of coating, granulation and mixing. 7. Способ получения стабильной пероральной фармацевтической композиции по п.5 или 6, отличающийся тем, что количество добавляемого желтого железооксидного пигмента и/или красного железооксидного пигмента составляет не менее 0,3 мас.% от массы таблетки.7. A method of obtaining a stable oral pharmaceutical composition according to claim 5 or 6, characterized in that the amount of added yellow iron oxide pigment and / or red iron oxide pigment is at least 0.3 wt.% By weight of the tablet. 8. Способ предотвращения изменений в профиле высвобождения лекарственного средства посредством добавления желтого железооксидного пигмента и/или красного железооксидного пигмента в количестве, эффективном для стабилизации препарата с пролонгированным высвобождением матричного типа, включающего лекарственное вещество, гидрофильное основание и полиэтиленоксид.8. A method of preventing changes in the release profile of a drug by adding yellow iron oxide pigment and / or red iron oxide pigment in an amount effective to stabilize the drug with a sustained release matrix type comprising the drug, hydrophilic base and polyethylene oxide. 9. Применение желтого железооксидного пигмента и/или красного железооксидного пигмента в количестве, эффективном для стабилизации препарата с пролонгированным высвобождением матричного типа, включающего лекарственное вещество, гидрофильное основание и полиэтиленоксид для предотвращения изменений профиля высвобождения лекарственного препарата.9. The use of yellow iron oxide pigment and / or red iron oxide pigment in an amount effective to stabilize the drug with a sustained release matrix type comprising a drug, a hydrophilic base and polyethylene oxide to prevent changes in the release profile of the drug.
RU2002102701/15A 1999-08-04 2000-08-01 Stable peroral gel-forming pharmaceutical composition, method for it preparing, method for prevention alteration in medicinal agent releasing, method for enhancement of physical stability of peroral composition RU2220715C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14722299P 1999-08-04 1999-08-04
US60/147,222 1999-08-04

Publications (2)

Publication Number Publication Date
RU2002102701A true RU2002102701A (en) 2003-11-10
RU2220715C2 RU2220715C2 (en) 2004-01-10

Family

ID=22520720

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002102701/15A RU2220715C2 (en) 1999-08-04 2000-08-01 Stable peroral gel-forming pharmaceutical composition, method for it preparing, method for prevention alteration in medicinal agent releasing, method for enhancement of physical stability of peroral composition

Country Status (17)

Country Link
EP (1) EP1205190B1 (en)
JP (1) JP3462490B2 (en)
KR (1) KR100507400B1 (en)
CN (1) CN1193792C (en)
AT (1) ATE324909T1 (en)
AU (1) AU769807B2 (en)
CA (1) CA2387705C (en)
DE (1) DE60027728T2 (en)
DK (1) DK1205190T3 (en)
ES (1) ES2262528T3 (en)
HU (1) HU229295B1 (en)
MX (1) MXPA02001267A (en)
NO (1) NO331834B1 (en)
PL (1) PL200645B1 (en)
PT (1) PT1205190E (en)
RU (1) RU2220715C2 (en)
WO (1) WO2001010466A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011529A (en) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevention and treatment of functional somatic disorders, including stress-related disorders.
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
JP2005162737A (en) * 2003-11-10 2005-06-23 Astellas Pharma Inc Sustained release medicinal composition
JP2005162736A (en) * 2003-11-10 2005-06-23 Astellas Pharma Inc Sustained release medicinal composition
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
JP4632204B2 (en) * 2005-09-21 2011-02-16 アステラス製薬株式会社 Antidiarrheal irritable bowel syndrome treatment
TWI478712B (en) 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
US20110300209A1 (en) * 2009-01-20 2011-12-08 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
SI2456424T1 (en) 2009-07-22 2013-10-30 Gruenenthal Gmbh Oxidation-stabilized tamper-resistant dosage form
RU2547555C2 (en) 2009-07-22 2015-04-10 Грюненталь Гмбх Hot-melt extruded pharmaceutical dosage form
PL2554168T3 (en) 2010-03-29 2018-05-30 Astellas Pharma Inc. Controlled release pharmaceutical composition
CN103269688A (en) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 Tamper resistant dosage form comprising inorganic salt
KR102027912B1 (en) 2011-02-15 2019-10-02 지엘팜텍주식회사 An oral sustained-release triple layer tablet comprising tamsulosin or pharmaceutically acceptable salts thereof
EA201400173A1 (en) 2011-07-29 2014-06-30 Грюненталь Гмбх SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES
CN103841964A (en) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 Tamper-resistant tablet providing immediate drug release
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
BR112015026549A2 (en) 2013-05-29 2017-07-25 Gruenenthal Gmbh tamper-proof dosage form containing one or more particles
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (en) 2014-05-26 2017-05-31 Грюненталь Гмбх DOSAGE FORM AS PARTICLE MULTIPLE, PROTECTED AGAINST CALLED DOSE RESET BY ETHANOL
ES2766424T3 (en) 2015-03-19 2020-06-12 Daiichi Sankyo Co Ltd Solid preparation containing oxidizing agent
EP3272346A4 (en) * 2015-03-19 2018-08-01 Daiichi Sankyo Company, Limited Solid preparation containing colorant
MX2017013637A (en) 2015-04-24 2018-03-08 Gruenenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction.
TWI722988B (en) 2015-06-05 2021-04-01 瑩碩生技醫藥股份有限公司 Slow-release pharmaceutical composition and preparation method thereof
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
ES2717534T3 (en) 2017-02-14 2019-06-21 Tiefenbacher Alfred E Gmbh & Co Kg Prodrugs of Mirabegron
CA3096246C (en) 2018-07-30 2023-09-05 Daiichi Sankyo Company, Limited Stabilizer-containing solid drug formulation
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
HU206824B (en) * 1990-08-24 1993-01-28 Biogal Gyogyszergyar Process for the production of a table crystallizing in the monoclinic system, which contains light-, heat-, and moisture- sensitive active agents
JP2820829B2 (en) * 1991-03-07 1998-11-05 武田薬品工業株式会社 Nucleated powder and production method thereof
JPH04346929A (en) * 1991-05-22 1992-12-02 Takada Seiyaku Kk Bromocriptine mesylate preparation having stability to light
WO1996032097A1 (en) * 1995-04-14 1996-10-17 Pharma Pass Solid compositions containing polyethyleneoxide and a non-amorphous active principle
DK0991409T3 (en) * 1997-08-01 2002-03-25 Elan Corp Plc Pharmaceutical controlled release tenagabine-containing preparations
DE69815003T2 (en) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition

Similar Documents

Publication Publication Date Title
RU2002102701A (en) Stable oral hydrogel-forming, pharmaceutical composition, method for its preparation, method for preventing changes in drug release, method for increasing physical stability of the oral composition
CA2387705A1 (en) Stable pharmaceutical composition for oral use
ATE324104T1 (en) CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING MESALAZINE
RU2004137118A (en) PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES AND METHOD OF ITS PRODUCTION
HUP0400382A2 (en) Sustained-release composition and process for producing the same
ATE123649T1 (en) SOLID PHARMACEUTICAL SUSTAINED RELEASE FORM.
DK158788A (en) PHARMACEUTICAL PREPARATION WITH SLOW RELEASE
IL111647A0 (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them
BR9808933A (en) Composition in the form of microcapsules or implants, process for the preparation of a water-soluble substance, active substance, triptorelin acetate, lanreotide acetate, or octreotide acetate, and double-stranded rna
HUP0203451A2 (en) Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
MY142403A (en) Oral dosage forms for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
EA200000584A3 (en) Solid thermoformable controlled-release pharmaceutical composition
CA2385890A1 (en) Controlled release compositions comprising nimesulide
CA2083639A1 (en) Substituted phenyl phenol leukotriene antagonists
CA2534664A1 (en) Modafinil compositions
ATE253354T1 (en) CAPSULES WITH COMPOSITIONS CONTAINING LORATADINE AND PSEUDOEPHEDRINE
MXPA04003506A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease.
SE0001916D0 (en) Novel formulation
CA2299464A1 (en) Controlled release pharmaceutical compositions containing tiagabine
HUP9904327A2 (en) Stabilised pharmaceutical compositions, with quinupristine and dalfopristine base and their preparation
JPS5668619A (en) Nifedipine-containing solid composition
TH20304EX (en) Controlled release formula containing tramadol
TH27939B (en) Pharmacy ingredient formula
TH18160A (en) Ipsapirone drug formula
JP2011231121A (en) Controlled release preparation coated with aqueous dispersion of acrylic polymer and method therefor